MRNA · Insider trading · 13F holders · Congress trades
Moderna, Inc. (MRNA)
Who is buying and selling MRNA: company insiders on SEC Form 4, hedge funds and superinvestors on Form 13F, and members of Congress under the STOCK Act. Every figure links to the filing or page it comes from.
- 13F filers holding
- 69
- Insider buys, 90 days
- $0
- Insider sales, 90 days
- $62.6M
- Congress trades, 12 months
- 3
MRNA at a glance
- Between Aug 1, 2026 and Oct 29, 2026, 4 MRNA insiders filed 5 sales worth $62.6M on SEC Form 4, and no open-market purchases; 5 of the sales were pre-planned under Rule 10b5-1.
- 69 13F filers hold MRNA among their 50 largest positions, worth $4.4B combined, including John Overdeck and David Siegel. The biggest bets by portfolio weight are Merck & Co., Inc. (30.7%), Beau Ventures, LLc (18.2%) and Step Capital Management Pte. Ltd. (15.0%). In their latest 13Fs, 5 managers opened a new position and 7 added to one.
- Members of Congress have disclosed 25 MRNA trades since 2020, 1 purchase and 2 sales in the past year; the latest was Maria Elvira Salazar (R-FL), selling $1K–15K on Sep 24, 2026.
- MRNA last closed at $222.76 on Oct 29, 2026.
MRNA insider trading
Between Aug 1, 2026 and Oct 29, 2026, 4 MRNA insiders filed 5 sales worth $62.6M on SEC Form 4, and no open-market purchases; 5 of the sales were pre-planned under Rule 10b5-1.
| Filed | Insider | Role | Trade | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|---|
| Oct 16, 2026 | Hoge Stephen | President | Sale10b5-1 | 78,369 | $217.10 | $17.0M | SEC |
| Sep 16, 2026 | Hoge Stephen | President | Sale10b5-1 | 80,575 | $145.10 | $11.7M | SEC |
| Sep 14, 2026 | Mock James M | Chief Financial Officer | Sale10b5-1 | 34,836 | $134.49 | $4.7M | SEC |
| Sep 3, 2026 | Klinger Shannon Thyme | Chief Legal Officer | Sale10b5-1 | 3,471 | $139.95 | $486K | SEC |
| Aug 7, 2026 | Bancel Stephane | Chief Executive Officer, Director | Sale10b5-1 | 499,246 | $57.52 | $28.7M | SEC |
Who owns MRNA? Hedge funds and superinvestors
69 13F filers hold MRNA among their 50 largest positions, worth $4.4B combined, including John Overdeck and David Siegel. The biggest bets by portfolio weight are Merck & Co., Inc. (30.7%), Beau Ventures, LLc (18.2%) and Step Capital Management Pte. Ltd. (15.0%). In their latest 13Fs, 5 managers opened a new position and 7 added to one.
Superinvestors holding MRNA: John Overdeck and David Siegel 0.4%
| Manager | % of portfolio | Value | Shares | Last quarter | 13F |
|---|---|---|---|---|---|
| Baillie Gifford & CoHedge fund | 1.2% | $1.3B | 18,206,778 | -8.9% shares | Q2 2026 |
| Theleme Partners LLPHedge fund | 33.5% | $564.3M | 8,057,571 | +0.1% shares | Q2 2026 |
| John Overdeck and David SiegelHedge fund | 0.4% | $503.8M | 7,193,530 | -20.8% shares | Q2 2026 |
| Banque Pictet & Cie SABank & trust | 4.0% | $414.3M | 2,151,259 | -20.3% shares | Q3 2026 |
| Flagship Pioneering, LLCHedge fund | 21.1% | $324.4M | 4,632,149 | +0.0% shares | Q2 2026 |
| Douglas Lane & Associates, LLCWealth manager | 3.0% | $223.6M | 1,160,945 | -13.6% shares | Q3 2026 |
| Beau Ventures, LLcWealth manager | 18.2% | $192.6M | 1,000,056 | -0.0% shares | Q3 2026 |
| Merck & Co., Inc.Corporation | 30.7% | $161.6M | 2,308,190 | +0.0% shares | Q2 2026 |
| Lingotto Investment Management LLPHedge fund | 2.5% | $144.3M | 749,208 | -1.9% shares | Q3 2026 |
| Bamco Inc /ny/Investment manager | 0.2% | $139.3M | 1,989,386 | — | Q2 2026 |
| Letko, Brosseau & Associates IncInstitutional asset manager | 0.8% | $50.8M | 724,830 | — | Q2 2026 |
| Telemark Asset Management, LLCHedge fund | 3.5% | $49.0M | 700,000 | +40.0% shares | Q2 2026 |
| Step Capital Management Pte. Ltd.Hedge fund | 15.0% | $48.7M | 695,000 | +7.8% shares | Q2 2026 |
| Susquehanna Portfolio Strategies, LLCBroker-dealer | 0.5% | $33.0M | 471,043 | — | Q2 2026 |
| Mount Capital LtdAsset manager | 12.1% | $32.1M | 457,900 | +15.9% shares | Q2 2026 |
| Leonteq Securities AGBroker-dealer | 2.4% | $29.3M | 152,218 | -43.0% shares | Q3 2026 |
| FNY Investment Advisers, LLCHedge fund | 5.2% | $20.7M | 107,610 | — | Q3 2026 |
| Plustick Management LLCHedge fund | 7.3% | $17.2M | 245,000 | +11.4% shares | Q2 2026 |
| China Universal Asset Management Co., Ltd.Asset manager | 0.8% | $14.8M | 72,845 | — | Q3 2026 |
| Group One Trading LLCInvestment manager | 0.4% | $14.3M | 203,915 | — | Q2 2026 |
| Twin Focus Capital Partners, LLCWealth manager | 1.3% | $13.0M | 185,601 | +0.0% shares | Q2 2026 |
| Legal Advantage Investments, Inc.Wealth manager | 2.7% | $12.6M | 65,175 | +36.7% shares | Q3 2026 |
| Simplex Trading, LLCInvestment manager | 0.3% | $10.8M | 154,558 | -29.6% shares | Q2 2026 |
| Eversept Partners, LPHedge fund | 0.6% | $10.7M | 152,122 | -4.7% shares | Q2 2026 |
| Westwood Wealth ManagementHedge fund | 3.0% | $10.2M | 53,065 | -0.1% shares | Q3 2026 |
| Patton Fund Management, Inc.Hedge fund | 2.3% | $8.8M | 45,656 | — | Q3 2026 |
| BOCHK Asset Management LtdAsset manager | 1.1% | $7.8M | 40,300 | — | Q3 2026 |
| Militia Capital Management LLCHedge fund | 1.4% | $7.6M | 108,701 | — | Q2 2026 |
| Green Alpha Advisors, LLCWealth manager | 4.3% | $6.4M | 33,191 | -1.7% shares | Q3 2026 |
| Gallagher Capital Advisors, LLCWealth manager | 3.2% | $6.0M | 11,652 | — | Q3 2026 |
The 30 largest of 69 positions, by value. Each manager counts with its latest 13F (Q3 2026: 32, Q2 2026: 36, Q1 2026: 1). Screen MRNA in the grand portfolio →
MRNA stock trades by members of Congress
Members of Congress have disclosed 25 MRNA trades since 2020, 1 purchase and 2 sales in the past year; the latest was Maria Elvira Salazar (R-FL), selling $1K–15K on Sep 24, 2026.
| Filed | Member | Trade | Amount | Traded | Since |
|---|---|---|---|---|---|
| Oct 7, 2026 | Maria Elvira SalazarR-FL · House | Sale | $1K–15K | Sep 24, 2026 | +14.5% |
| Sep 9, 2026 | Maria Elvira SalazarR-FL · House | Buy | $1K–15K | Aug 19, 2026 | +27.9% |
| Sep 9, 2026 | Maria Elvira SalazarR-FL · House | Sale | $1K–15K | Aug 19, 2026 | +27.9% |
| May 8, 2025 | Robert P. Bresnahan, Jr.R-PA · House | Sale | $1K–15K | Apr 8, 2025 | +805.1% |
| Mar 27, 2025 | Robert P. Bresnahan, Jr.R-PA · House | Buy | $1K–15K | Feb 25, 2025 | +570.1% |
| Feb 12, 2025 | Julie JohnsonD-TX · House | Sale | $1K–15K | Jan 15, 2025 | +541.4% |
| Mar 7, 2024 | Josh GottheimerD-NJ · House | Sale | $1K–15K | Feb 1, 2024 | +125.2% |
| Oct 15, 2023 | Josh GottheimerD-NJ · House | Sale | $1K–15K | Sep 15, 2023 | +94.6% |
| Aug 13, 2023 | Daniel S. GoldmanD-NY · House | Sale | $50K–100K | Jul 12, 2023 | +77.1% |
| May 19, 2023 | Daniel S. GoldmanD-NY · House | Buy | $50K–100K | Apr 10, 2023 | +39.3% |
| Apr 20, 2023 | Josh GottheimerD-NJ · House | Buy | $1K–15K | Mar 31, 2023 | +45.2% |
| Apr 17, 2023 | Daniel S. GoldmanD-NY · House | Sale | $50K–100K | Mar 6, 2023 | +54.8% |
| Apr 17, 2022 | Josh GottheimerD-NJ · House | Sale | $1K–15K | Mar 16, 2022 | +31.7% |
| Aug 9, 2021 | Josh GottheimerD-NJ · House | Sale | $1K–15K | Jul 22, 2021 | -31.1% |
| Apr 21, 2021 | Josh GottheimerD-NJ · House | Sale | $1K–15K | Mar 15, 2021 | +55.2% |
| Apr 21, 2021 | Marie NewmanD-IL · House | Sale | $15K–50K | Jan 29, 2021 | +28.8% |
| Apr 21, 2021 | Marie NewmanD-IL · House | Sale | $1K–15K | Jan 29, 2021 | +28.8% |
| Apr 15, 2021 | Marie NewmanD-IL · House | Sale | $15K–50K | Jan 29, 2021 | +28.8% |
| Apr 15, 2021 | Marie NewmanD-IL · House | Sale | $1K–15K | Jan 29, 2021 | +28.8% |
| Feb 13, 2021 | Marie NewmanD-IL · House | Buy | $1K–15K | Jan 22, 2021 | +70.2% |
6 members have traded MRNA: Maria Elvira Salazar, Robert P. Bresnahan, Jr., Julie Johnson, Josh Gottheimer, Daniel S. Goldman, Marie Newman.
Analysis mentioning MRNA
Posts from the blog that cover Moderna, Inc., newest first.
- Insider selling · Oct 16, 2026Insider Selling on October 16, 2026: INSW, P and NTRA Lead $282.2M of Sales
- Congress trades · Oct 7, 2026Congress Stock Trades Filed October 7, 2026: 44 Trades by Maria Salazar and Josh Gottheimer
- Congress trades · Sep 9, 2026Congress Stock Trades Filed September 9, 2026: 94 Trades by April McClain Delaney, Maria Salazar and More
MRNA questions and answers
Are insiders buying MRNA stock?
Between Aug 1, 2026 and Oct 29, 2026, 4 MRNA insiders filed 5 sales worth $62.6M on SEC Form 4, and no open-market purchases; 5 of the sales were pre-planned under Rule 10b5-1.
Which hedge funds own MRNA?
69 13F filers hold MRNA among their 50 largest positions, worth $4.4B combined, including John Overdeck and David Siegel. The biggest bets by portfolio weight are Merck & Co., Inc. (30.7%), Beau Ventures, LLc (18.2%) and Step Capital Management Pte. Ltd. (15.0%). In their latest 13Fs, 5 managers opened a new position and 7 added to one.
Has Congress traded MRNA?
Members of Congress have disclosed 25 MRNA trades since 2020, 1 purchase and 2 sales in the past year; the latest was Maria Elvira Salazar (R-FL), selling $1K–15K on Sep 24, 2026.
Who is the largest holder of MRNA?
Among 13F filers, Baillie Gifford & Co reports the largest MRNA position, $1.3B (18,206,778 shares) in its Q2 2026 13F. The biggest bet by portfolio weight is Merck & Co., Inc.'s: 30.7% of its portfolio.
Cite or share this
Free to use with a link back. The data updates every filing day.